Financial Performance & Growth - Q3 2025 total revenue reached $87.3 million, a 69% year-over-year increase[10] - Q3 2025 U S net product sales were $40.7 million, a 31% year-over-year increase[10] - Retail prescription equivalents increased by 9% quarter-over-quarter[11] Market Access & Awareness - Achieved 87% Medicare and 86% commercial approval rates for NEXLETOL and NEXLIZET, with average $29/$36 copays for a 30-day supply[16] - Launched a connected-TV ad campaign on Hulu and Disney+, expected to deliver approximately 18 million impressions targeting adults 50+ with prior statin use[16] Statin Intolerance & Bempedoic Acid - Up to 30% of U S adults experience some degree of statin intolerance[18] - Approximately 29% of patients discontinue their statin within the first year[31] - In the CLEAR Outcomes trial, bempedoic acid demonstrated a 13% relative risk reduction (RRR) in the primary composite endpoint (MACE-4) compared to placebo[48] - In primary prevention patients, bempedoic acid showed a 32% RRR in MACE-4 compared to placebo[52] Clinical Trial Data - CLEAR Outcomes trial showed a 27% RRR in nonfatal myocardial infarction with bempedoic acid compared to placebo[48] - CLEAR Outcomes trial showed a 19% RRR in coronary revascularization with bempedoic acid compared to placebo[48]

Financial Performance - U S net product revenue of NEXLETOL® and NEXLIZET® grew approximately 109% year-over-year to $134 million in Q1 2022[9, 27] - Royalty and Partner revenue increased approximately 244% year-over-year to $55 million in Q1 2022[9] - Q1 2022 Operational Expenses decreased 32% year-over-year[9] - The company ended Q1 2022 with $2685 million in cash, cash equivalents, restricted cash, and investment securities[9] Prescription Growth - Quarterly Retail Prescription Equivalents (RPE) grew +567% year-over-year and +65% quarter-over-quarter[9] Clinical Trial Progress - The CLEAR Outcomes trial is approaching 95% MACE accumulation, with 100% MACE expected by year-end and topline results anticipated in Q1 2023[9, 20] - The CLEAR Outcomes trial is a 14,014-patient randomized, double-blind, placebo-controlled clinical trial with a median follow-up anticipated to be 375 years[20] Market Opportunity - The company is progressing its pipeline, including an oral PCSK9 inhibitor and an ACL inhibitor platform, which will participate in a market valued at over $11 billion in 2026[19] Financial Outlook - FY 2022 Research and Development (R&D) guidance is $100 - $110 million[27] - FY 2022 Selling, General & Administrative (SG&A) guidance is $120 - $130 million[27] - FY 2022 Operating Expense (Op Ex) guidance is $220 - $240 million[27]